Literature DB >> 29080014

[Available transvenous occluder designs and implantation techniques].

P Sick1, T Lewalter2.   

Abstract

In this article, most of the present or available in the near future left atrial appendage (LAA) occlusion devices are discussed in terms of structure of the devices and principle technique for implantation. Thus, the Watchman™ device from Boston, the Amulet™ device from Abbot, the Lambre™ device from Lifetech, the Occlutech® device from Occlutech®, and the WaveCrest® device from Biosense Webster (former Coherex) are discussed. The systems differ in terms of the concept of occlusion. Several devices consist of only one part (Watchman™ and Occlutech®) that is implanted in the body, ending up in the orifice of the LAA. Others like the Amulet™ or Lambre™ device have an additional disc covering the orifice of the LAA from the left atrial side. The distal anchoring system is implanted first in the body of the LAA; thereafter, the disc is placed upon the orifice. With the WaveCrest® device, covering of the orifice is performed as the first step followed by rolling in the anchoring system to fix the device to the body of the LAA.

Keywords:  Atrial fibrillation; LAA occlusion; Prevention; Stroke; Thrombembolic events

Mesh:

Year:  2017        PMID: 29080014     DOI: 10.1007/s00399-017-0533-z

Source DB:  PubMed          Journal:  Herzschrittmacherther Elektrophysiol        ISSN: 0938-7412


  6 in total

1.  Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation: a randomized clinical trial.

Authors:  Vivek Y Reddy; Horst Sievert; Jonathan Halperin; Shephal K Doshi; Maurice Buchbinder; Petr Neuzil; Kenneth Huber; Brian Whisenant; Saibal Kar; Vijay Swarup; Nicole Gordon; David Holmes
Journal:  JAMA       Date:  2014-11-19       Impact factor: 56.272

2.  Left atrial appendage occlusion with the AMPLATZER Amulet device: an expert consensus step-by-step approach.

Authors:  Apostolos Tzikas; Sameer Gafoor; David Meerkin; Xavier Freixa; Ignacio Cruz-Gonzalez; Thorsten Lewalter; Jacqueline Saw; Sergio Berti; Jens Erik Nielsen-Kudsk; Reda Ibrahim; Dhanunjaya Lakkireddy; Vincent Paul; Dabit Arzamendi; Fabian Nietlispach; Stephen G Worthley; David Hildick-Smith; Jean Benoit Thambo; Claudio Tondo; Adel Aminian; Zbigniew Kalarus; Boris Schmidt; Lars Sondergaard; Joelle Kefer; Bernhard Meier; Jai-Wun Park; Horst Sievert; Heyder Omran
Journal:  EuroIntervention       Date:  2016-04-20       Impact factor: 6.534

3.  Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial.

Authors:  David R Holmes; Saibal Kar; Matthew J Price; Brian Whisenant; Horst Sievert; Shephal K Doshi; Kenneth Huber; Vivek Y Reddy
Journal:  J Am Coll Cardiol       Date:  2014-07-08       Impact factor: 24.094

4.  A new left atrial appendage occluder (Lifetech LAmbre Device) for stroke prevention in atrial fibrillation.

Authors:  Yat-Yin Lam
Journal:  Cardiovasc Revasc Med       Date:  2013 May-Jun

5.  Initial worldwide experience with the WATCHMAN left atrial appendage system for stroke prevention in atrial fibrillation.

Authors:  Peter B Sick; Gerhard Schuler; Karl Eugen Hauptmann; Eberhard Grube; Steve Yakubov; Zoltan G Turi; Gregory Mishkel; Steve Almany; David R Holmes
Journal:  J Am Coll Cardiol       Date:  2007-03-21       Impact factor: 24.094

6.  Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial.

Authors:  David R Holmes; Vivek Y Reddy; Zoltan G Turi; Shephal K Doshi; Horst Sievert; Maurice Buchbinder; Christopher M Mullin; Peter Sick
Journal:  Lancet       Date:  2009-08-15       Impact factor: 79.321

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.